Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Definitive chemoradiotherapy with cisplatin with cisplatin plus 5-fluorouracil is the
standard in Western countries in esophagus cancer.But in China because of its toxic reaction,
most of patients stop the halfway.Because low toxicity, Capecitabine is widely used in the
chemotherapy of esophageal cancer.
The purpose of this experiment was to study the different cycle on capecitabine with
chemotherapy for esophageal cancer chemoradiation effect.We are prepared to within 2 years
study recruited 200 patients with esophageal cancer.The primary endpoint is overall survival
and the secondary endpoints include progression-free survival, response rate,pathologic
complete response rate and adverse events.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Henan University of Science and Technology